Related Experiment Video
Updated: Feb 17, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification
Fiona Tsui-Fen Cheng1, Fu Ou-Yang2,3, Nina Lapke4
1Breast Cancer Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei City
Abstract:
Treatment options for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer and resistance to endocrine therapy remain limited. An interesting therapeutic target in these patients is fibroblast growth factor receptor 1 (FGFR1). FGFR1 is amplified in approximately 11% of patients with breast cancer, especially those with HR+ disease. This report presents a patient with metastatic HR+ HER2- breast cancer harboring an FGFR1 amplification who was resistant to endocrine therapy but responded to pazopanib, a multi-tyrosine kinase inhibitor with FGFR-inhibiting activity. Upon pazopanib treatment, the patient's brain lesions nearly disappeared, and she experienced therapeutic changes in the lung and an improvement of liver function. This case suggests that pazopanib may be a promising agent for the treatment of patients with breast cancer and FGFR1 amplifications.
Insights
Limited treatment options exist for endocrine therapy-resistant hormone receptor-positive (HR+) HER2-negative breast cancer. A patient with FGFR1 amplification responded well to pazopanib, showing significant improvement in brain, lung, and liver lesions.
Area of Science:
- Oncology
- Medical Genetics
Background:
- Hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer often develops resistance to endocrine therapy, limiting treatment options.
- Fibroblast growth factor receptor 1 (FGFR1) amplification is observed in approximately 11% of breast cancers, particularly HR+ disease, presenting a potential therapeutic target.
Observation:
- This report details a patient with metastatic HR+ HER2- breast cancer and an FGFR1 amplification.
- The patient was resistant to standard endocrine therapy.
Findings:
- The patient responded positively to pazopanib, a multi-tyrosine kinase inhibitor with FGFR-inhibiting properties.
- Pazopanib treatment led to near-complete resolution of brain metastases.
- Therapeutic changes were observed in lung lesions, and liver function improved.
Implications:
- Pazopanib demonstrates potential as a treatment for patients with breast cancer harboring FGFR1 amplifications.
- This case highlights the clinical relevance of targeting FGFR1 in endocrine-resistant HR+ HER2- breast cancer.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
06:59Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
Published on: May 12, 2023
